Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
We have reported that mice with an intracerebral (i.c.) malignant glioma or breast cancer treated with i.c. injection of allogeneic fibroblasts genetically engineered to secrete interleukin-2 (IL-2) survived longer than mice in various control groups. The goal of the present study was to determine the effectiveness of utilizing IL-2 secreting allogeneic fibroblasts as a protective treatment to prevent the development of an i.c. glioma or breast carcinoma. Using an intracranial microcannula system that we developed, the animals received weekly injections of the cellular vaccine prior to the introduction of tumor cells via the cannula. The results demonstrate a significant delay (P < 0.005) in the development of glioma in the animals pre-treated with either allogeneic non-secreting or IL-2-secreting fibroblasts prior to introduction of tumor cells. In addition, 50% of the animals pre-treated with IL-2 secreting allogeneic fibroblasts injected subsequently with G1261 glioma cells did not develop a tumor, while all of the animals injected with glioma cells alone and 92% of those treated with non-secreting fibroblasts eventually died. The long-term survivors from the pre-treatment group were subsequently re-challenged with tumor and compared to naive controls. There was evidence that long-term immunity was established in the pre-treated animals, since there was a significant prolongation of survival (P < 0.01). In similar experiments using breast cancer cells, 62% of the animals pre-treated with non-secreting allogeneic fibroblasts and 75% of the animals pre-treated with allogeneic IL-2 secreting fibroblasts subsequently injected with SB-5b breast carcinoma cells did not develop tumors and had a significant prolongation of survival. These data suggest that i.c. injection of allogeneic IL-2 secreting fibroblasts are effective as a protective treatment in the prevention of the development of a brain tumor when the fibroblasts are introduced into the same site where the tumor is subsequently injected.
Glick
Roberta P
RP
Department of Neurosurgery, Cook County Hospital, Chicago, Illinois 60612, USA. rpglick@hotmail.com
Lichtor
Terry
T
Panchal
Ripul
R
Mahendra
Anjuli
A
Cohen
Edward P
EP
D000230:Adenocarcinoma / Q000503:physiopathology / Q000517:prevention & control; D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D001943:Breast Neoplasms / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D005347:Fibroblasts / Q000378:metabolism* / Q000637:transplantation*; D005910:Glioma / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D007109:Immunity; D007376:Interleukin-2 / Q000378:metabolism*; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous
D007376:Interleukin-2